openPR Logo
Press release

Kaposi Sarcoma Treatment Market Competitive Landscape

06-26-2018 03:49 PM CET | Health & Medicine

Press release from: Pharmaceutical Report

Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS) disease or drugs prescribed post organ transplantation surgery are highly susceptible to HHV-8: a heterovirus, which contributes to the development of Kaposi sarcoma. Organ transplant patients are prescribed immunosuppressive agents to prevent their body from rejecting the graft, which increases their susceptibility towards Kaposi sarcoma associated herpesvirus (KSHV) infection. The long-term use of these agents increases the rate of risk of these patients by over 100 times as compared to the general population.

Click To Continue Reading :
https://www.coherentmarketinsights.com/ongoing-insight/kaposi-sarcoma-treatment-market-1671

Kaposi Sarcoma Treatment Market Drivers

Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma is one of the major factors driving the adoption of Highly Active Antiretroviral Therapy (HAART) therapy, which subsequently drives growth of the Kaposi sarcoma treatment market. For instance, according to the American Cancer Society (ACS), February 2016 data findings, around 1 in 200 transplant patients in the U.S. suffer from Kaposi sarcoma. In the U.S., Kaposi sarcoma is much more common among men than women, and is rarely observed among children. Additionally, according to the same source, it is more common among African Americans than in whites in the U.S in 2016.

Get The Holistic SAMPLE With Research Methodology:
https://www.coherentmarketinsights.com/insight/request-sample/1671

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Kaposi Sarcoma Treatment Market Competitive Landscape here

News-ID: 1098770 • Views:

More Releases from Pharmaceutical Report

Pharmaceutical Robots Market Forecast 2018- 2026: Kawasaki Heavy Industries,
Pharmaceutical Robots Market Forecast 2018- 2026: Kawasaki Heavy Industries,
Kawasaki Heavy Industries Ltd. (Japan), FANUC Corporation (Japan), KUKA AG (Germany), Mitsubishi Electric Corporation (Japan), ABB Ltd. (Switzerland), Denso Corporation (Japan), Seiko Epson Corporation (Japan), Marchesini Group S.p.A (Italy), Universal Robots A/S (Denmark), Kawasaki Heavy Industries ,Yaskawa Electric Corporation (Japan), and Shibuya Corporation (Japan) are the prominent players in the global pharmaceutical robots market. The global pharmaceutical robots market is anticipated to reach 452.7 million by 2025 and estimated to reach
Grow Owning to Innovations In Oncology Nutrition Market
Grow Owning to Innovations In Oncology Nutrition Market
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
FMD Vaccine Market - Shield against Economic Loss
FMD Vaccine Market - Shield against Economic Loss
Foot and Mouth Disease (FMD) causes repetitive outbreak around world thereby causing economic and social damage. Preventing foot and mouth disease is the only sustainable and viable options, which can be done only though the vaccination for FMD, which is expected to drive growth of the foot and mouth disease vaccine market. According to paper published by the Food and Agricultural Organization (FAO) and World Organization for Animal Health (OIE),
Divalproex Sodium Market Competitive Landscape,Regional Insights
Divalproex Sodium Market Competitive Landscape,Regional Insights
Increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. For instance, according to study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally. Moreover, rising patient pool

All 5 Releases


More Releases for Kaposi

Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma
Kaposi Sarcoma Market: High incidence of HIV/AIDS associated Kaposi sarcoma is o …
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
04-04-2017 | Health & Medicine
TMR
Kaposi Sarcoma Market: Patent Expiry of Blockbuster Drugs for Treatment of Kapos …
Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the
Kaposi Sarcoma Market: North America Leads Global Market despite Lower Incidence …
According to the U.S. Centers for Disease Control and Prevention, Kaposi sarcoma (KS) is considered to be an AIDS-defining disease, indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was reportedly high in homosexual men with HIV. The market for Kaposi sarcoma is characterized by the increasing number of domestic players playing an important role in their respective regional markets. Given the patent expiry of